Friday, October 30, 2026

Back to today

From X

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Short CNM

Core & Main faces a short thesis centered on the risks in its roll-up strategy.

Short LUMN

Lumen Technologies faces a fading boost from its PCF-related sugar high.

Nomad Foods - The Yield Machine

Nomad Foods combines leading European frozen-food brands with a high dividend yield, buybacks and decade-low valuation, while private-label…

Visa: The Investment Case Summary

Visa earns roughly 0.5% of transaction value for authorising, clearing and settling payments across its global network, supporting high…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

286 firms

Sectors

Ordered by how often our editor reaches for them.